Latus Bio Raises $43M Series A Extension to Advance Precision Gene Therapy Platform

Precision doesn’t beg for attention, it earns it in the data, then cashes the check when capital follows. Latus Bio, Inc. just stepped into that lane with a $43M Series A extension, pushing its total Series A haul to $97M. Not loud money. Smart money. The kind that shows up when the science starts talking back.

P. Peter Ghoroghchian, M.D., Ph.D. (CEO) built this with intention, not illusion. Philadelphia roots, Boston Seaport edge, and a platform born out of serious AAV research that doesn’t just chase precision, it demands it. This is translational medicine that actually translates, from pipette to patient, with fewer gaps between discovery and delivery.

But this isn’t a solo act, it’s a tightly run orchestra. Ainslie Little, Ph.D. (COO) keeps the machine operationally sharp. Jang-Ho Cha, M.D., Ph.D. (Chief Science and Medical Officer) drives the scientific thesis with clinical gravity. John Connelly, MBA (Chief Development Officer) pushes programs forward where timelines get real. Katie Hewitt (interim CBO) connects the dots on strategy and partnerships. Then you’ve got execution depth with George Yohrling, Ph.D. (Executive Director, Program Management), Jenna Soper, Ph.D. (Executive Director, Program Management), and Suus Plezier (Executive Director, Clinical Operations) making sure this doesn’t stay theoretical.

8VC leaned in again to lead, with DCVC Bio, BioAdvance, Benjamin Franklin Technology Partners, Modi Ventures, Gaingels, and Hatch BioFund doubling down. Korea Development Bank and Helen’s Pink Sky Foundation didn’t wander in случайно, they showed up because the signal is getting louder.

And the signal lives in the pipeline. LTS-101 already cleared the FDA gate for CLN2 disease with IND status plus Fast Track, Orphan Drug, and Rare Pediatric Disease designations. LTS-201 is lining up Huntington’s disease with an IND target set for Q3 2026. Same platform, different battles, one underlying bet that delivery is everything.

The deeper play sits under the hood. High-throughput capsid discovery meets AI/ML, building a system that learns, compounds, and reuses its own wins. Most are still crafting one-off therapies. Latus Bio, Inc. is building a repeatable engine, something that scales without losing precision.

And when you zoom out, the bench gets even deeper. Beverly Davidson, Ph.D. (Founder, SAB Chair) anchors the scientific roots, with Sarah Tabrizi, FRCP, FMedSci, Ph.D., Angela Schulz, M.D., Rebecca Ahrens-Nicklas, M.D., Ph.D., Pranam Chatterjee, Ph.D., and Philip Kim, Ph.D. reinforcing the edge. On the board, Francisco Gimenez, Ph.D. (8VC), Kiersten Stead, Ph.D. (DCVC Bio), and David Piacquad, MBA bring capital discipline with operator scars.

The capital is in. The platform is defined. Now it becomes a question of execution under clinical pressure, where timelines tighten, data speaks louder, and platforms either prove they scale or get exposed trying. Gene therapy has always promised precision, but scale is the part that separates a breakthrough from a business.